Clinical Study of LV009 Injection in the Treatment of Recurrent/Refractory CD19 Positive Blood Tumors

NCT07330895 · clinicaltrials.gov ↗

EARLY_PHASE1

Phase

NOT_YET_RECRUITING

Status

19

Enrollment

OTHER

Sponsor class

Conditions

CD19+ Relapse/Refractory B-ALL

Interventions

DRUG: Biological: LV009 injection

Sponsor

The First Affiliated Hospital with Nanjing Medical University